论文部分内容阅读
目的:探讨Hepsin在前列腺癌组织中的表达,并分析其与前列腺癌临床分期及病理分级之间的关系。方法:免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连结(SP)法检测68例前列腺癌、40例前列腺增生组织中Hepsin蛋白的表达,并分析其与临床分期、病理分级之间的关系。结果:Hepsin蛋白在前列腺癌组织和前列腺增生组织中阳性表达率分别为86.76%(59/68)和45.00%(18/40),差异有统计学意义,χ2=21.47,P<0.001;其阳性率在前列腺癌不同临床分期中差异有统计学意义(χ2=9.07,P=0.004),而在Glea-son评分高与低分组之间差异无统计学意义,χ2=1.15,P=0.476。结论:Hepsin可作为前列腺癌的一个诊断指标,其与前列腺癌临床分期密切相关,有可能在前列腺癌的发生发展中起重要作用。
Objective: To investigate the expression of Hepsin in prostate cancer and to analyze its relationship with clinical stage and pathological grade of prostate cancer. Methods: The expression of Hepsin protein in 68 cases of prostate cancer and 40 cases of benign prostatic hyperplasia was detected by immunohistochemical streptavidin-peroxidase-linked (SP) method. The relationship between Hepsin protein and clinicopathologic grade and pathological grade relationship. Results: The positive rates of Hepsin protein in prostate cancer and benign prostatic hyperplasia tissues were 86.76% (59/68) and 45.00% (18/40) respectively, the difference was statistically significant (χ2 = 21.47, P <0.001) There was no significant difference between the high and low Glea-son scores (χ2 = 1.15, P = 0.476) in different clinical stages of prostate cancer (χ2 = 9.07, P = 0.004). Conclusion: Hepsin can be used as a diagnostic indicator of prostate cancer, which is closely related to the clinical stage of prostate cancer and may play an important role in the development of prostate cancer.